Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

2.8K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
2.8K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

443
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
443
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
Hormonal Regulation01:33

Hormonal Regulation

35.6K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

708
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
708

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same author

Reprogramming of Iron and Oxygen Metabolism Across the Spectrum of Primary Aldosteronism.

medRxiv : the preprint server for health sciences·2026
Same author

Nonclassic congenital adrenal hyperplasia and bilateral pheochromocytomas in a patient with a germline pathogenic <i>MAX</i> variant.

JCEM case reports·2026
Same author

Incremental Prognostic Value of Subendocardial Myocardial Flow Reserve in Patients With Normal Perfusion.

Circulation·2026
Same author

Aldosterone-targeted Therapy after Primary Aldosteronism Testing in Resistant Hypertension: A Nationwide Cohort Study.

medRxiv : the preprint server for health sciences·2026
Same author

Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Jan 10, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.1K

Subclinical primary aldosteronism.

Stéfanie Parisien-La Salle1,2, Jenifer M Brown1,3, Cheng Hsuan Tsai1,4,5

  • 1Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Archives of Endocrinology and Metabolism
|November 28, 2025
PubMed
Summary
This summary is machine-generated.

Subclinical primary aldosteronism (PA) is an early form of PA found in people with normal or mild hypertension. It significantly increases risks for hypertension, cardiovascular issues, and kidney disease, necessitating early detection and intervention.

Keywords:
Aldosteroneadrenalprimary aldosteronismreninsubclinical primary aldosteronism

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.5K
Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.1K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.5K
Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.5K

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Primary aldosteronism (PA) is a key factor in hypertension and cardiovascular disease.
  • Subclinical PA, an early stage of PA, is present in individuals with normal or mild hypertension.
  • Evidence from histopathology, biochemistry, proteomics, and genetics supports subclinical PA identification.

Purpose of the Study:

  • To highlight the clinical relevance of subclinical PA in cardiorenal disease pathogenesis.
  • To emphasize the need for improved early detection methods for subclinical PA.
  • To assess the impact of early aldosterone-targeted interventions on clinical outcomes.

Main Methods:

  • Review of histopathological findings.
  • Analysis of hormonal biochemistry.
  • Integration of proteomic and genetic study evidence.
  • Longitudinal study data analysis.

Main Results:

  • Subclinical PA is associated with increased risk of developing hypertension.
  • Subclinical PA contributes to adverse cardiovascular remodeling and events.
  • Subclinical PA is linked to an increased risk of chronic kidney disease.

Conclusions:

  • Subclinical PA plays a significant role in the development of cardiorenal disease.
  • Early detection of subclinical PA is crucial for patient outcomes.
  • Further research on aldosterone-directed interventions is warranted to prevent adverse clinical outcomes.